ESMO 2023

My highlights of ESMO23 in metastatic breast cancer

DATO-DX - where is it going?

5 year follow-up

Preoperative checkpointinihition in ER+ disease

Highlights in eBC

Remarkable efficacies in patients with HER2+ mBC with brain metastases

When the history of ADC is written: Redefining first-line standard of care in mUC!

Lu-PSMA leads forward

The FGFR story in bladder cancer at ESMO23

Clearing up non-clear cell RCC

New 3rd line therapy for RCC

Early use of enzalutamide in advanced prostate cancer

Tarlatamab in SCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

My highlights from ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

ALINA - immediate change of practice!

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

What was the most exciting news at ESMO23?

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

What is your definition of triple-negative breast cancer?

New and better biomarkers are needed!

Anticipated updates and exciting new data for checkpointinhibitors

5 year follow-up

MonarchE - trial update

Pembrolizumab solidifies as SOC in early-stage TNBC

New data on neoadjuvant immunotherapy

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Consolidation of data in early HR+ and triple-negative breast cancer

Negative EFS results from NeoTrip

ER-low corresponds diagnostically to ER-0 breast cancer

My highlights of ESMO23 in early breast cancer

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

Preoperative checkpointinihition in ER+ disease

Highlights in eBC

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Carry-over effects in monarchE confirmed

Analysis of tumour microenvironment and immunophenotype in TNBC

Detailed view of nodal-negative patients

Clinically relevant effect of pembro also in PCR

Our guidelines are correct

Ribociclib effective in all subtypes

Immunoncology in eBC - triple negative and more?

HR+ study with > 20 % PCR

Punti salienti in eBC

Nouvelles données sur l'immunothérapie néoadjuvante

MonarchE - mise à jour de l'essai

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

Studio NeoTrip: negativi i risultati

What was the most exciting news at ESMO23?

New ADC for metastatic breast cancer?

New targets, new linker, new ADCs - much more to learn with new therapies!

Improvement of therapy outcome by app-based patient education

How to organize a molecular tumorboards in breast cancer?

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

Robust data from the monarchE

TROP2 expression as a potential mechanism of resistance in HER2+ patients

T-DXd in HER2+ patients with brain metastases

Highlights in mBC

New ADC in HR+ disease

ADC + Immunotherapy - the BEGONIA study paradigm

Still on track for success in HER2-low MBC

Our guidelines are correct

Duvalumab + Dato-DXd effective

Even more new generation ADCs in breast cancer?

T-DXd also effective for brain metastases

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Improved oncological therapy with the smartphone

Fulvestran better than anastrozole, but no survival benefit

Abemaciclib remains consistent in 5-year follow-up

Can surgery be spared following primary systemic therapy?

TULIP: Trastuzumab duocarmazine without OS benefit

My highlights of ESMO23 in metastatic breast cancer

T-DXd - new standard of care for brain mets?

Dato-DXd - new player in advanced luminal disease

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

Benefit for SG even after intensive pretreatment

OP seems to be dispensable for super responders

DATO-DX - where is it going?

HS20089 - a novel ADC is coming for TNBC

HER2DX in the PHERgain trial

Patient-centered molecular medicine - a new approach

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

HER2DX en el estudio PHERgain

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

Lo studio BEGONIA nelle paziento con tumore triplo negativo

T-DXd - nowy standard postępowania w przerzutach do mózgu?

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

Punti salienti in mBC

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Targeted therapy will move forward - but more robust data is needed.

What is the future of immune therapy in prostate cancer?

Should we use zoledronic acid in all ADT patients?

Negative data for pembrolizumab in mHSCPC & mCRPC

Osteoprotection at mHSPC

Big data and AI prediction tools

Brave New World in mCRPC

EMBARK - Quality of Life

ENZA P:Trial and controversies

Immunotherapy in metastatic PCa

Early use of enzalutamide in advanced prostate cancer

RADICALS RT: Trial and controversies

Salvage radiotherapy the new standard

Combination of radioligand therapy with chemotherapy useful

Embark without fear

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

PSMA FORE: Trial and controversies

Precision medicine at mCRCP

Lu-PSMA leads forward

IO therapy in metastatic prostate cancer.

CXCR2 inhibitor in PCa

EMBARK expands ENZA indication to PCa

TITAN: ultra-low PSA = best prognosis

PSMAfore unleashes urooncologic opportunity

Longterm toxicity of adjuvant RT after prostatectomy

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

EMBARK och livskvalitet

Immunterapi vid prostatacancer

CXCR2 hämmare och prostatacancer

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

STAMPEDE data. Skelettstärkande och riskstratifiering.

Big Data och AI för prediktion vid prostatacancer

Part 2: New standard of care in first line urothelial cancer!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part1: New standard of care in first line urothelial cancer?!

New SoC in firstline bladder cancer

Unique bladder delivery system of gemcitabine herolds remarkable response

EV + Pembro as standard of care in first-line therapy of bladder cancer

Chemo-IO establishes itself in the first-line treatment of bladder cancer

When the history of ADC is written: Redefining first-line standard of care in mUC!

DAD, DAD-IO

Amazing new data in bladder cancer

The FGFR story in bladder cancer at ESMO23

FGFR inhibitors: What is the best scenario for this family of compounds?

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Is de-escalating therapy ready for prime-time?

Where does the future therapy go in renal cell carcinoma?

Important new treatment option but only for subset of patients?

Intermittent therapy also possible with TKIs

Belzutifan - whats next kidney cancer?

Clearing up non-clear cell RCC

Kidney cancer highlights at ESMO23

Belzutifan in later lines of therapy

New 3rd line therapy for RCC

New mode of action in mRCC - ready for prime time?

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Perioperative IO: OS-benefi from KEYNOTE-671

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Circulating DNA in AEGEAN trial

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Big improvements in early stage and a subset of metatstic NSCLC

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

ALINA - immediate change of practice!

Substantial improvement in local regional NSCLC

Scene is set for inductive immunotherapy

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

My highlights from ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

I miei punti salienti di ESMO 2023

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Les points forts de l'ESMO 2023

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Activating EGFR-mutation - what's coming up?

ESMO2023-impact on everyday practice!

Evolving landscape of ADCs

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Does immunotherapy still have a place in EGFR-positive mNSCLC?

My highlights from ESMO 2023

TROPION-Lung01: positive development

Practice changing results on exon 20 insertion mNSCLC

Big improvements in early stage and a subset of metatstic NSCLC

Do ADCs have brain activity?

Substantial improvement in rare alterations

Treatment sequences for EGFR-mutated Patients

PAPILLON - bringing together therapy for the 1st line

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Brain metastases – options to improve the systemic treatment

MARIPOSA II: Trial and controversies

Changing treatment landscape in EGFR-mutated NSCLC

MARIPOSA: Trial and controversies

LIBRETO - a positive study, but was it necessary?

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Amivantamab upfront? MARIPOSA trial

NRG fusions: a new drugable target?

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Amivantamab at progression? MARIPOSA-2 trial

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

By unanimous decision and still the champion – docetaxel!

Les points forts de l'ESMO 2023

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

I miei punti salienti di ESMO 2023

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Quelles séquences thérapeutiques pour les patients EGFR mutés

Amivantamab at progression? MARIPOSA-2 trial

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Amivantamab upfront? MARIPOSA trial

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Impact of T-cell engagers in SCLC

A new option in relapsed SCLC

New hope for patients with SCLC

Tarlatamab in SCLC

Neue Hoffnung für Patienten mit SCLC

PCO Therapeutics

Update on gynaecological cancers

New data on sarkomas

New data on H&N Cancer

First data on luveltamab in multiline treatment for endometrial cancer

Precision oncology in CUP

Evolution of the revolution - the RUBY trial